Arab Finance: Ibnsina Pharma (ISPH) recorded a 31.5% year-on-year (YoY) increase in consolidated net profits after tax and non-controlling interest in the first half (H1) of 2026 to EGP 511.299 million, versus EGP 388.807 million, the firm disclosed.
Net sales came in at EGP 41.492 billion in the January-June period this year, up from EGP 35.045 billion in the same period last year.
The company’s standalone net profits after tax stood at EGP 486.625 million in H1 2026, rising from EGP 378 million in the corresponding half a year ago.
Meanwhile, standalone net sales increased to EGP 41.213 billion from EGP 34.904 billion.
Established in 2001, Ibnsina Pharma is the second-largest pharmaceutical distributor in Egypt, distributing products from over 350 global and local companies to more than 46,000 customers of pharmacies, hospitals, wholesalers, and healthcare institutions.
